Ligand-based design and synthesis of N'-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies

Herein, a series of N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas their antifungal activi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of enzyme inhibition and medicinal chemistry 2022-12, Vol.37 (1), p.1098-1119
Hauptverfasser: Ezz Eldin, Rogy R., Saleh, Marwa A., Alotaibi, Mohammad Hayal, Alsuair, Reem K., Alzahrani, Yahya A., Alshehri, Feras A., Mohamed, Amany F., Hafez, Shaimaa M., Althoqapy, Azza Ali, Khirala, Seham K., Amin, Mona M., A. F, Yousuf, AbdElwahab, Azza H., Alesawy, Mohamed S., Elmaaty, Ayman Abo, Al-Karmalawy, Ahmed A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1119
container_issue 1
container_start_page 1098
container_title Journal of enzyme inhibition and medicinal chemistry
container_volume 37
creator Ezz Eldin, Rogy R.
Saleh, Marwa A.
Alotaibi, Mohammad Hayal
Alsuair, Reem K.
Alzahrani, Yahya A.
Alshehri, Feras A.
Mohamed, Amany F.
Hafez, Shaimaa M.
Althoqapy, Azza Ali
Khirala, Seham K.
Amin, Mona M.
A. F, Yousuf
AbdElwahab, Azza H.
Alesawy, Mohamed S.
Elmaaty, Ayman Abo
Al-Karmalawy, Ahmed A.
description Herein, a series of N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas their antifungal activities were screened against C. albicans. Compounds 4a, 4h, and 4i showed the most promising antibacterial and antifungal activities. Moreover, compounds 4h and 4i being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via in vivo testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. Highlights A series of new N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein. The newly synthesised compounds were assessed through in vitro, in vivo, and in silico approaches. Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas, their antifungal activities were screened against C. albicans. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species. Compounds (4h and 4i) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via in vivo testing using bio-chemical analysis and liver/kidney histological examination. A molecular docking study and ADMET in silico studies were performed. A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.
doi_str_mv 10.1080/14756366.2022.2063282
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_35430934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c03d2a86a53447f6abf2741a1f54b2f8</doaj_id><sourcerecordid>2727915994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-73e0944825f5a40d4a03e6797f195fc79554f1e07df75e60cfb9faa151208b673</originalsourceid><addsrcrecordid>eNp9UstuFDEQHCEQCYFPAFniAIdM8NszQkKEiEekCCQeZ6tnxt51NGsvtnfD5Gv4Fq78FN7sJiIcuNjd1dXltl1V9ZjgI4Ib_IJwJSST8ohiSssiGW3onWp_g9eSKX73JpZyr3qQ0jnGlFDC71d7THCGW8b3q99nbgZ-qDtIZkCDSW7mUQFQmnyelzShYNHHZ_Ub4y-n0Q3Gm5od8npwC5Pn4cfUlUKYT0OEy1ItEtGtIbu1SQgSWoZsfHYwFtHsFq6PobvKZgVOL5FZw7gq9OBRNyHnf_1cuxzD4S5cl2gzjfMoudH1AcFyGQP0ZTR04fIcfTn-jFJeDc6kh9U9C2Myj3b7QfXt3duvJx_qs0_vT0-Oz-peSJprxQxuOW-osAI4HjhgZqRqlSWtsL1qheCWGKwGq4SRuLddawGIIBQ3nVTsoDrd6g4BzvUyugXESQdw-goIcaYhZtePRveYDRQaCYJxrqyEzlLFCRAreEdtU7RebbWWq25hhr68SoTxlujtindzPQtr3WKmSIOLwPOdQAzfVyZlvXCpN-MI3oRV0lSK4pCWtrJQn_5DPQ-r6MtTaaqoaoloW15YYssqX5VSNPZmGIL1xnr62np6Yz29s17pe_L3TW66rr1WCK-3BOdtiAu4CHEcdIZpDNFG8L1Lmv3_jD8Tpe3v</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2727915994</pqid></control><display><type>article</type><title>Ligand-based design and synthesis of N'-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>MEDLINE</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Ezz Eldin, Rogy R. ; Saleh, Marwa A. ; Alotaibi, Mohammad Hayal ; Alsuair, Reem K. ; Alzahrani, Yahya A. ; Alshehri, Feras A. ; Mohamed, Amany F. ; Hafez, Shaimaa M. ; Althoqapy, Azza Ali ; Khirala, Seham K. ; Amin, Mona M. ; A. F, Yousuf ; AbdElwahab, Azza H. ; Alesawy, Mohamed S. ; Elmaaty, Ayman Abo ; Al-Karmalawy, Ahmed A.</creator><creatorcontrib>Ezz Eldin, Rogy R. ; Saleh, Marwa A. ; Alotaibi, Mohammad Hayal ; Alsuair, Reem K. ; Alzahrani, Yahya A. ; Alshehri, Feras A. ; Mohamed, Amany F. ; Hafez, Shaimaa M. ; Althoqapy, Azza Ali ; Khirala, Seham K. ; Amin, Mona M. ; A. F, Yousuf ; AbdElwahab, Azza H. ; Alesawy, Mohamed S. ; Elmaaty, Ayman Abo ; Al-Karmalawy, Ahmed A.</creatorcontrib><description>Herein, a series of N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas their antifungal activities were screened against C. albicans. Compounds 4a, 4h, and 4i showed the most promising antibacterial and antifungal activities. Moreover, compounds 4h and 4i being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via in vivo testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. Highlights A series of new N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein. The newly synthesised compounds were assessed through in vitro, in vivo, and in silico approaches. Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas, their antifungal activities were screened against C. albicans. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species. Compounds (4h and 4i) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via in vivo testing using bio-chemical analysis and liver/kidney histological examination. A molecular docking study and ADMET in silico studies were performed. A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.</description><identifier>ISSN: 1475-6366</identifier><identifier>ISSN: 1475-6374</identifier><identifier>EISSN: 1475-6374</identifier><identifier>DOI: 10.1080/14756366.2022.2063282</identifier><identifier>PMID: 35430934</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Acinetobacter ; Anti-Bacterial Agents - chemistry ; Anti-Infective Agents - pharmacology ; antibacterial ; Antibacterial activity ; antifungal ; Antifungal Agents - chemistry ; Antimicrobial activity ; Antimicrobial agents ; Biochemical analysis ; Candida albicans ; E coli ; Escherichia coli ; in vitro ; in vivo ; Kidneys ; Ligands ; Liver ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Molecular Docking Simulation ; Molecular Structure ; N'-benzylidene-3,4-dimethoxybenzohydrazide ; Pharmacokinetics ; Pseudomonas aeruginosa ; Research Paper ; SAR ; Staphylococcus aureus ; Structure-Activity Relationship ; Toxicity</subject><ispartof>Journal of enzyme inhibition and medicinal chemistry, 2022-12, Vol.37 (1), p.1098-1119</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-73e0944825f5a40d4a03e6797f195fc79554f1e07df75e60cfb9faa151208b673</citedby><cites>FETCH-LOGICAL-c562t-73e0944825f5a40d4a03e6797f195fc79554f1e07df75e60cfb9faa151208b673</cites><orcidid>0000-0003-0767-9864 ; 0000-0002-8173-6073</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037180/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037180/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35430934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ezz Eldin, Rogy R.</creatorcontrib><creatorcontrib>Saleh, Marwa A.</creatorcontrib><creatorcontrib>Alotaibi, Mohammad Hayal</creatorcontrib><creatorcontrib>Alsuair, Reem K.</creatorcontrib><creatorcontrib>Alzahrani, Yahya A.</creatorcontrib><creatorcontrib>Alshehri, Feras A.</creatorcontrib><creatorcontrib>Mohamed, Amany F.</creatorcontrib><creatorcontrib>Hafez, Shaimaa M.</creatorcontrib><creatorcontrib>Althoqapy, Azza Ali</creatorcontrib><creatorcontrib>Khirala, Seham K.</creatorcontrib><creatorcontrib>Amin, Mona M.</creatorcontrib><creatorcontrib>A. F, Yousuf</creatorcontrib><creatorcontrib>AbdElwahab, Azza H.</creatorcontrib><creatorcontrib>Alesawy, Mohamed S.</creatorcontrib><creatorcontrib>Elmaaty, Ayman Abo</creatorcontrib><creatorcontrib>Al-Karmalawy, Ahmed A.</creatorcontrib><title>Ligand-based design and synthesis of N'-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies</title><title>Journal of enzyme inhibition and medicinal chemistry</title><addtitle>J Enzyme Inhib Med Chem</addtitle><description>Herein, a series of N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas their antifungal activities were screened against C. albicans. Compounds 4a, 4h, and 4i showed the most promising antibacterial and antifungal activities. Moreover, compounds 4h and 4i being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via in vivo testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. Highlights A series of new N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein. The newly synthesised compounds were assessed through in vitro, in vivo, and in silico approaches. Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas, their antifungal activities were screened against C. albicans. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species. Compounds (4h and 4i) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via in vivo testing using bio-chemical analysis and liver/kidney histological examination. A molecular docking study and ADMET in silico studies were performed. A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.</description><subject>Acinetobacter</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Infective Agents - pharmacology</subject><subject>antibacterial</subject><subject>Antibacterial activity</subject><subject>antifungal</subject><subject>Antifungal Agents - chemistry</subject><subject>Antimicrobial activity</subject><subject>Antimicrobial agents</subject><subject>Biochemical analysis</subject><subject>Candida albicans</subject><subject>E coli</subject><subject>Escherichia coli</subject><subject>in vitro</subject><subject>in vivo</subject><subject>Kidneys</subject><subject>Ligands</subject><subject>Liver</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Structure</subject><subject>N'-benzylidene-3,4-dimethoxybenzohydrazide</subject><subject>Pharmacokinetics</subject><subject>Pseudomonas aeruginosa</subject><subject>Research Paper</subject><subject>SAR</subject><subject>Staphylococcus aureus</subject><subject>Structure-Activity Relationship</subject><subject>Toxicity</subject><issn>1475-6366</issn><issn>1475-6374</issn><issn>1475-6374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9UstuFDEQHCEQCYFPAFniAIdM8NszQkKEiEekCCQeZ6tnxt51NGsvtnfD5Gv4Fq78FN7sJiIcuNjd1dXltl1V9ZjgI4Ib_IJwJSST8ohiSssiGW3onWp_g9eSKX73JpZyr3qQ0jnGlFDC71d7THCGW8b3q99nbgZ-qDtIZkCDSW7mUQFQmnyelzShYNHHZ_Ub4y-n0Q3Gm5od8npwC5Pn4cfUlUKYT0OEy1ItEtGtIbu1SQgSWoZsfHYwFtHsFq6PobvKZgVOL5FZw7gq9OBRNyHnf_1cuxzD4S5cl2gzjfMoudH1AcFyGQP0ZTR04fIcfTn-jFJeDc6kh9U9C2Myj3b7QfXt3duvJx_qs0_vT0-Oz-peSJprxQxuOW-osAI4HjhgZqRqlSWtsL1qheCWGKwGq4SRuLddawGIIBQ3nVTsoDrd6g4BzvUyugXESQdw-goIcaYhZtePRveYDRQaCYJxrqyEzlLFCRAreEdtU7RebbWWq25hhr68SoTxlujtindzPQtr3WKmSIOLwPOdQAzfVyZlvXCpN-MI3oRV0lSK4pCWtrJQn_5DPQ-r6MtTaaqoaoloW15YYssqX5VSNPZmGIL1xnr62np6Yz29s17pe_L3TW66rr1WCK-3BOdtiAu4CHEcdIZpDNFG8L1Lmv3_jD8Tpe3v</recordid><startdate>202212</startdate><enddate>202212</enddate><creator>Ezz Eldin, Rogy R.</creator><creator>Saleh, Marwa A.</creator><creator>Alotaibi, Mohammad Hayal</creator><creator>Alsuair, Reem K.</creator><creator>Alzahrani, Yahya A.</creator><creator>Alshehri, Feras A.</creator><creator>Mohamed, Amany F.</creator><creator>Hafez, Shaimaa M.</creator><creator>Althoqapy, Azza Ali</creator><creator>Khirala, Seham K.</creator><creator>Amin, Mona M.</creator><creator>A. F, Yousuf</creator><creator>AbdElwahab, Azza H.</creator><creator>Alesawy, Mohamed S.</creator><creator>Elmaaty, Ayman Abo</creator><creator>Al-Karmalawy, Ahmed A.</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-0767-9864</orcidid><orcidid>https://orcid.org/0000-0002-8173-6073</orcidid></search><sort><creationdate>202212</creationdate><title>Ligand-based design and synthesis of N'-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies</title><author>Ezz Eldin, Rogy R. ; Saleh, Marwa A. ; Alotaibi, Mohammad Hayal ; Alsuair, Reem K. ; Alzahrani, Yahya A. ; Alshehri, Feras A. ; Mohamed, Amany F. ; Hafez, Shaimaa M. ; Althoqapy, Azza Ali ; Khirala, Seham K. ; Amin, Mona M. ; A. F, Yousuf ; AbdElwahab, Azza H. ; Alesawy, Mohamed S. ; Elmaaty, Ayman Abo ; Al-Karmalawy, Ahmed A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-73e0944825f5a40d4a03e6797f195fc79554f1e07df75e60cfb9faa151208b673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acinetobacter</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Infective Agents - pharmacology</topic><topic>antibacterial</topic><topic>Antibacterial activity</topic><topic>antifungal</topic><topic>Antifungal Agents - chemistry</topic><topic>Antimicrobial activity</topic><topic>Antimicrobial agents</topic><topic>Biochemical analysis</topic><topic>Candida albicans</topic><topic>E coli</topic><topic>Escherichia coli</topic><topic>in vitro</topic><topic>in vivo</topic><topic>Kidneys</topic><topic>Ligands</topic><topic>Liver</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Structure</topic><topic>N'-benzylidene-3,4-dimethoxybenzohydrazide</topic><topic>Pharmacokinetics</topic><topic>Pseudomonas aeruginosa</topic><topic>Research Paper</topic><topic>SAR</topic><topic>Staphylococcus aureus</topic><topic>Structure-Activity Relationship</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ezz Eldin, Rogy R.</creatorcontrib><creatorcontrib>Saleh, Marwa A.</creatorcontrib><creatorcontrib>Alotaibi, Mohammad Hayal</creatorcontrib><creatorcontrib>Alsuair, Reem K.</creatorcontrib><creatorcontrib>Alzahrani, Yahya A.</creatorcontrib><creatorcontrib>Alshehri, Feras A.</creatorcontrib><creatorcontrib>Mohamed, Amany F.</creatorcontrib><creatorcontrib>Hafez, Shaimaa M.</creatorcontrib><creatorcontrib>Althoqapy, Azza Ali</creatorcontrib><creatorcontrib>Khirala, Seham K.</creatorcontrib><creatorcontrib>Amin, Mona M.</creatorcontrib><creatorcontrib>A. F, Yousuf</creatorcontrib><creatorcontrib>AbdElwahab, Azza H.</creatorcontrib><creatorcontrib>Alesawy, Mohamed S.</creatorcontrib><creatorcontrib>Elmaaty, Ayman Abo</creatorcontrib><creatorcontrib>Al-Karmalawy, Ahmed A.</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ezz Eldin, Rogy R.</au><au>Saleh, Marwa A.</au><au>Alotaibi, Mohammad Hayal</au><au>Alsuair, Reem K.</au><au>Alzahrani, Yahya A.</au><au>Alshehri, Feras A.</au><au>Mohamed, Amany F.</au><au>Hafez, Shaimaa M.</au><au>Althoqapy, Azza Ali</au><au>Khirala, Seham K.</au><au>Amin, Mona M.</au><au>A. F, Yousuf</au><au>AbdElwahab, Azza H.</au><au>Alesawy, Mohamed S.</au><au>Elmaaty, Ayman Abo</au><au>Al-Karmalawy, Ahmed A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ligand-based design and synthesis of N'-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies</atitle><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle><addtitle>J Enzyme Inhib Med Chem</addtitle><date>2022-12</date><risdate>2022</risdate><volume>37</volume><issue>1</issue><spage>1098</spage><epage>1119</epage><pages>1098-1119</pages><issn>1475-6366</issn><issn>1475-6374</issn><eissn>1475-6374</eissn><abstract>Herein, a series of N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised to target the multidrug efflux pump (MATE). The antibacterial activities were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas their antifungal activities were screened against C. albicans. Compounds 4a, 4h, and 4i showed the most promising antibacterial and antifungal activities. Moreover, compounds 4h and 4i being the broader and superior members regarding their antimicrobial effects were selected to be further evaluated via in vivo testing using biochemical analysis and liver/kidney histological examination. Additionally, molecular docking was carried out to attain further deep insights into the synthesised compounds' binding modes. Also, ADMET studies were performed to investigate the physicochemical/pharmacokinetics features and toxicity parameters of the synthesised derivatives. Finally, a structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future. Highlights A series of new N'-benzylidene-3,4-dimethoxybenzohydrazide derivatives were designed and synthesised targeting the multidrug efflux pump (MATE) guided by the pharmacophoric features of the co-crystallized native inhibitor of the target protein. The newly synthesised compounds were assessed through in vitro, in vivo, and in silico approaches. Using the agar well diffusion assay, the antibacterial activities of the synthesised compounds were screened against S. aureus, Acinetobacter, S. typhi, E. coli, and P. aeruginosa, whereas, their antifungal activities were screened against C. albicans. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) of the synthesised compounds were investigated on variable microbial species. Compounds (4h and 4i) -as the broader and superior members regarding their antimicrobial effects- were further evaluated via in vivo testing using bio-chemical analysis and liver/kidney histological examination. A molecular docking study and ADMET in silico studies were performed. A structure-antimicrobial activity relationship study was established to facilitate further structural modifications in the future.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>35430934</pmid><doi>10.1080/14756366.2022.2063282</doi><tpages>22</tpages><orcidid>https://orcid.org/0000-0003-0767-9864</orcidid><orcidid>https://orcid.org/0000-0002-8173-6073</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-6366
ispartof Journal of enzyme inhibition and medicinal chemistry, 2022-12, Vol.37 (1), p.1098-1119
issn 1475-6366
1475-6374
1475-6374
language eng
recordid cdi_pubmed_primary_35430934
source Open Access: PubMed Central; Taylor & Francis Open Access; MEDLINE; Directory of Open Access Journals; EZB Electronic Journals Library
subjects Acinetobacter
Anti-Bacterial Agents - chemistry
Anti-Infective Agents - pharmacology
antibacterial
Antibacterial activity
antifungal
Antifungal Agents - chemistry
Antimicrobial activity
Antimicrobial agents
Biochemical analysis
Candida albicans
E coli
Escherichia coli
in vitro
in vivo
Kidneys
Ligands
Liver
Microbial Sensitivity Tests
Minimum inhibitory concentration
Molecular Docking Simulation
Molecular Structure
N'-benzylidene-3,4-dimethoxybenzohydrazide
Pharmacokinetics
Pseudomonas aeruginosa
Research Paper
SAR
Staphylococcus aureus
Structure-Activity Relationship
Toxicity
title Ligand-based design and synthesis of N'-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T14%3A05%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ligand-based%20design%20and%20synthesis%20of%20N'-Benzylidene-3,4-dimethoxybenzohydrazide%20derivatives%20as%20potential%20antimicrobial%20agents;%20evaluation%20by%20in%C2%A0vitro,%20in%C2%A0vivo,%20and%20in%20silico%20approaches%20with%20SAR%20studies&rft.jtitle=Journal%20of%20enzyme%20inhibition%20and%20medicinal%20chemistry&rft.au=Ezz%20Eldin,%20Rogy%20R.&rft.date=2022-12&rft.volume=37&rft.issue=1&rft.spage=1098&rft.epage=1119&rft.pages=1098-1119&rft.issn=1475-6366&rft.eissn=1475-6374&rft_id=info:doi/10.1080/14756366.2022.2063282&rft_dat=%3Cproquest_pubme%3E2727915994%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2727915994&rft_id=info:pmid/35430934&rft_doaj_id=oai_doaj_org_article_c03d2a86a53447f6abf2741a1f54b2f8&rfr_iscdi=true